3D bioprinting lobule-like hepatorganoids with induced vascularization for orthotopic implantation by Jianing Yan, Zhichao Ye, Yiwei Lu, Yuyang Yuan, Xiaofeng Wang, Tingting Yan, Jun Yin, Yifan Wang

“…Eventually, our findings demonstrate that this system effectively forms orthotopic implantation of hepatorganoids and facilitates vascularization, which may notably contribute to the understanding of transplantation, drug screening, and replacement therapy.…”
Get full text

Potentially commercializable nerve guidance conduits for peripheral nerve injury: Past, present, and future by Chundi Liu, Mouyuan Sun, Lining Lin, Yaxian Luo, Lianjie Peng, Jingyu Zhang, Tao Qiu, Zhichao Liu, Jun Yin, Mengfei Yu

“…To enhance comprehension of clinical situations, this article provides a comprehensive analysis of the clinical efficacy of nerve conduits approved by the United States Food and Drug Administration. It proposes that the initial six months post-transplantation is a critical window period for evaluating their efficacy. …”
Get full text

Construction of a circadian rhythm-related gene signature for predicting the prognosis and immune infiltration of breast cancer by Lin Ni, Lin Ni, He Li, Yanqi Cui, Wanqiu Xiong, Shuming Chen, Hancong Huang, Zhiwei Wang, Hu Zhao, Hu Zhao, Hu Zhao, Bing Wang, Bing Wang, Bing Wang

“…We also evaluated the association of the model’s risk score with immune cells and immune checkpoint genes, and analyzed prognostic genes and drug sensitivity in this model.ResultsWe screened 62 DEGs, including 30 upregulated genes and 32 downregulated genes, and performed GO and KEGG analysis on them. …”
Get full text

Curcumin-enhanced NIR-II-responsive gold nanobipyramids for targeted HSP 90 inhibition by Zhenying Diao, Youcheng Liang, Yong Liu, Dou Zhang, Long Qiu, Jianbo Sun, Qiaoyou Lu, Yanlei Liu, Daxiang Cui, Ting Yin

“…The nanoplatforms were assembled from NIR-II-responsive gold nanobipyramids (GNBs) combined with curcumin (Cur) via hydrophobic-hydrophobic interactions and hydrogen bonds. On the basis of drug discovery and network pharmacology, we found that Cur has impressive anti-HSP90 capability and analyzed its therapeutic mechanism against NSCLC. …”
Get full text

Recent advances in the role of high-salt diet in anti- and pro-cancer progression by Shiwei Tang, Juan Xu, Ping Wan, Ping Wan, Ping Wan, Shumen Jin, Ying Zhang, Ying Zhang, Linting Xun, Linting Xun, Jinli Wang, Jinli Wang, Mei Luo, Mei Luo, Wenjie Chen, Wenjie Chen, Zan Zuo, Zan Zuo, Zan Zuo, Hui Tang, Hui Tang, Jialong Qi, Jialong Qi, Jialong Qi, Jialong Qi, Jialong Qi

Get full text

Genetic and Molecular Characterization of Avian Influenza A(H9N2) Viruses from Live Bird Markets (LBM) in Senegal by Mamadou Malado Jallow, Moussa Moise Diagne, Marie Henriette Dior Ndione, Mamadou Aliou Barry, Ndiendé Koba Ndiaye, Davy Evrard Kiori, Marie Pedapa Mendy, Déborah Goudiaby, Gamou Fall, Malick Fall, Ndongo Dia

“…The A/H9N2 strains carried the low pathogenicity RSSR/GLF motif at the HA cleavage site and possessed several key amino acid mutations, including HA-I155T and HA-Q226L, which are associated with human host adaptation, PB2-T105V, PB2-A661T, and PB2-A588V, which are linked to the human-to-human transmission and increased polymerase activity, NS2-T14M, NS2-M100I, NS1-I106M, NS1-V222M, NS1-E223A, NS1-I226V, NS1-E227G, and NS1-P228S, which are known to alter virulence (increased or reduced) in humans or mice, and M2-S31N, which promotes drug resistance. Seven potential N-glycosylation sites were predicted in the HA protein and six in the NA protein. …”
Get full text

Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis [version 2; peer review: 1 approve... by Spyridon Siafis, Johannes Schneider-Thoma, Alexandra Bannach-Brown, Oliver D. Howes, Virginia Chiocchia, Ulf Tölch, Natascha I. Drude, Sabine M. Hölter, Andrea de Bartolomeis, Anthony C. Vernon, Georgia Salanti, Sridhar Natesan, Stefan Leucht, Irene Bighelli, Sameer Jauhar, Ioannis Mantas, Josef Priller, Francesca Tinsdeall, Wulf-Peter Hansen, Fiona J. Ramage, Nobuyuki Nomura, Malcolm R. Macleod

“…Therefore, we aim to synthesize evidence on the preclinical efficacy of muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis to provide unique insights and evidence-based information to guide drug development. Methods We plan a systematic review and meta-analysis of in vivo animal studies comparing muscarinic receptor agonists or positive allosteric modulators with control conditions and existing D2R-blocking antipsychotics in animals subjected to any method that induces behavioural changes of relevance for psychosis. …”
Get full text

Survey on first-line therapeutic management of relapsing–remitting multiple sclerosis in clinical practice in Spain by M. Llaneza, G. Fontes, L. Benedito-Palos, E. Moral

“…According to over 87% of the specialists, the latter drug was considered the most appropriate treatment for patients with liver disorders, who intended to become pregnant, and who presented low disease activity. …”
Get full text

Toxoplasma gondii in dromedary camels (Camelus dromedarius) in Egypt: a comparative seroepidemiological study in Upper and Lower Egypt by Ehab Kotb Elmahallawy, Ehab Kotb Elmahallawy, Nady Khairy Elbarbary, David Cano-Terriza, David Cano-Terriza, Tomás Fajardo, Nada Oudah Albalawi, Débora Jiménez-Martín, Marwa M. I. Ghallab, Ahmed Gareh, Refaat Ras, Refaat Ras, Isabelle Villena, Sabry A. S. Sadek, Hajar AlQadeeb, Hind Alzaylaee, Sonia Almería, Ignacio García-Bocanegra, Ignacio García-Bocanegra

Get full text

Women's experiences and acceptability of self-administered, home delivered, intravaginal 5-Fluorouracil cream for cervical precancer treatment in Kenya by Konyin Adewumi, Aparna Ghosh Kachoria, Everlyn Adoyo, Mercy Rop, Mercy Rop, Antony Owaya, Jennifer H. Tang, Jennifer H. Tang, Lisa Rahangdale, Lisa Rahangdale, Lisa Rahangdale, Chemtai Mungo, Chemtai Mungo, Chemtai Mungo

“…The main challenges included correctly measuring the study drug, finding a private place at home to self-administer, and the need to use condoms during treatment. …”
Get full text

Assessment of Bowel Preparation Using Low-Volume Sulphate-Based Preparations in Comparison with Macrogols: A Multicenter, Randomized, Comparative Clinical Study of the 3rd Phase by E. D. Fedorov, V. V. Veselov, S. V. Kashin, E. V. Tikhomirova, A. V. Veselov, D. V. Zavyalov, A. Kornowski, T. E. Gorskaya, M. Volteau, T. Ponchon

“…The corrected difference between the groups was -0.5 % (95 % CI: -4.2–3.3), thereby demonstrating “no less effective” of OSS as compared to Macrogol. Compliance with the drug use regime was higher in the OSS group than in the Macrogol group (95.7 % versus 82.3 %, respectively, p-value = 0.0011, ITT-population).The most common symptom reported in patients was nausea (27.9 % in the OSS group and 12.9 % in the Macrogol group). …”
Get full text

Russian Non-Interventional Study of the Efficacy and Tolerability of Rifaximin-α Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Prac... by O. S. Shifrin, E. A. Poluektova, A. V. Korolev, T. I. Semenova, M. V. Shein, G. N. Leksikova, O. A. Tokareva, O. E. Davydova, P. S. Andreev, S. E. Katorkin, A. A. Chernov, A. V. Zhuravlev, O. S. Sek, A. A. Kopina, N. Yu. Samokhina, Yu. V. Gorozhankina, M. F. Samigullin, V. S. Groshilin, E. N. Borisova, T. A. Petrova, I. Yu. Pirogova, S. V. Mednikov, N. V. Smagin, A. S. Sarsenbaeva, N. V. Smirnova, L. G. Kirsanova, N. M. Malyutina, M. A. Smirnova, E. N. Shleikova, V. T. Ivashkin

“…This observational (non-interventional) study was aimed at obtaining data on practitioners’ commitment to prescribing rifaximin-α therapy to patients with uncomplicated diverticular disease (UDD), to assess patients’ adherence to such prescriptions, as well as to assess physicians’ and patients’ satisfaction with this drug under the conditions of outpatient practice.Materials and methods. 27 research physicians in 22 research centres located in 15 Russian cities and 250 patients participated in an open, prospective multicentre observational study. …”
Get full text

Chemogenomic Screening in a Patient‐Derived 3D Fatty Liver Disease Model Reveals the CHRM1‐TRPM8 Axis as a Novel Module for Targeted Intervention by Sonia Youhanna, Aurino M. Kemas, Shane C. Wright, Yi Zhong, Britta Klumpp, Kathrin Klein, Aikaterini Motso, Maurice Michel, Nicole Ziegler, Mingmei Shang, Pierre Sabatier, Aimo Kannt, Hongda Sheng, Nuria Oliva‐Vilarnau, Florian A. Büttner, Brinton Seashore‐Ludlow, Jonas Schreiner, Maike Windbergs, Martin Cornillet, Niklas K. Björkström, Andreas J. Hülsmeier, Thorsten Hornemann, Jesper V. Olsen, Yi Wang, Roberto Gramignoli, Michael Sundström, Volker M. Lauschke

“…Combined, this study presents the first patient‐derived 3D MASH model, identifies a novel signaling module with anti‐fibrotic effects, and highlights the potential of organotypic culture systems for phenotype‐based chemogenomic drug target identification at scale.…”
Get full text

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis by Sandra M Herrmann, Riley Fadden, Ryan J Sullivan, Kerry L Reynolds, Harish Seethapathy, Meghan E Sise, Shruti Gupta, Alexandra-Chloe Villani, Qiyu Wang, Daiana Moreno, Destiny Harden, R Neal Smith, Ivy A Rosales, Robert B Colvin, Sarah Chute, Lynn D Cornell, Nancy J Yang, Sara Barmettler, Sophia Wells, Jocelyn Farmer

“…The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls.Results sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). …”
Get full text

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target by Cèlia Dobaño-López, Juan García Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Fabian Arenas, Marta Grau, Cristina López, Irene López-Oreja, Neus Serrat, Ares Martínez-Farran, Lluís Hernández, Heribert Playa-Albinyana, Rubén Giménez, Silvia Beà, Elías Campo, Jean-Michel Lagarde, Armando López-Guillermo, Laura Magnano, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán

“…In conclusion, FL-PDLS maintains the crosstalk between malignant B cells and the immune LN-TME and constitutes a robust and multiplexed pre-clinical tool to perform drug screening in a patient-derived system, advancing toward personalized therapeutic approaches.…”
Get full text

Epidemiology and Resistance Profiles of Bacteria Isolated From Blood Samples in Septic Patients at Emergency Department Admission: A 6-Year Single Centre Retrospective Analysis Fro... by Valeria Cento, Sara Carloni, Riccardo Sarti, Linda Bussini, Zian Asif, Paola Morelli, Francesco De Fazio, Federica Maria Tordato, Maddalena Casana, Debora Mondatore, Antonio Desai, Elena Generali, Nicola Pugliese, Elena Costantini, Massimo Vanoni, Maurizio Cecconi, Stefano Aliberti, Giorgio Da Rin, Erminia Casari, Michele Bartoletti, Antonio Voza

“…Methods: Clinical and microbiological data from 992 BSI cases (1,135 isolates) diagnosed within 24 h of ED admission at IRCCS Humanitas Research Hospital, Milan, Italy (January 2015–June 2022), were analysed. Drug resistance was interpreted using EUCAST-2023. …”
Get full text

Leveraging genomic insights from the neglected malaria parasites P. malariae and P. ovale using selective whole genome amplification (SWGA) approach by Fathia Ben-Rached, Amit Kumar Subudhi, Chang Li, Mariah Alawi, Rohit Satyam, Sui Xu, Guoding Zhu, Raeece Naeem, Sara Mfarrej, Di Liu, Zenaida Stead, Caroline Askonas, Yaobao Liu, Jun Cao, Arnab Pain

“…Conclusions SWGA approach implemented here provides a powerful tool for enhancing genomic analysis of these neglected parasites, revealing population diversity, drug resistance markers, and hypervariable regions. …”
Get full text

Recurrent adenoid cystic carcinoma of the left upper palate accompanied by massive maxillary hemorrhage: a case report and literature review by ZHANG Wangru, CHEN Yuanyuan, LI Zhiping, MENG Jian

“…With the addition of radiotherapy and immune-targeted drug treatment, tumor progression was effectively controlled, leading to an improved quality of life for the patient, who successfully survived for 129 months with the tumor by July 2024. …”
Get full text

A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in... by Thomas R. Moench, Lakshmi Botta, Brian Farrer, Jason D. Lickliter, Hyunah Kang, Yoona Park, Cheolmin Kim, Marshall Hoke, Miles Brennan, Morgan D. McSweeney, Zachary Richardson, John B. Whelan, Jong Moon Cho, Soo Young Lee, Frances Faurot, Jeff Hutchins, Samuel K. Lai

“…Study staff and participants were blinded to treatment assignment, except for pharmacy staff preparing the study drug. The ratio of active:placebo randomization to each cohort was set at 3:1. …”
Get full text

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

“…The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Foundation Medicine test (FoundationOneCDx) at TMB≥10 mut/Mb as a companion diagnostic (CDx) for single-agent pembrolizumab in second+line. …”
Get full text